GET DAILY SIGNALSWhy Is Korro Bio (KRRO) Stock Down -3.69% Today?
Key Takeaways
- KRRO shares were down about 3.69% in Tuesday's session, trading near $15.15 after closing the prior session at $15.73.
- The decline looks like profit-taking and consolidation after a sharp multi-session rebound, with no single company-specific catalyst identified.
- Momentum had been driven by a better-than-expected Q3 earnings report and progress across the KRRO-121 and KRRO-111 clinical programs.
- As a thinly traded, high-beta small-cap biotech, KRRO routinely posts outsized daily swings relative to the broader market.
- Traders are watching for follow-through on pipeline milestones, including interim data from the ANCHOR Phase 1/2 trial.
- For additional details on valuation, upcoming catalysts, and analyst expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- You can also discover AI-driven trading strategies covering this and thousands of other tickers on the Trending AI Robots page.
Opening Summary
Korro Bio, Inc. (KRRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company developing RNA-editing genetic medicines using its proprietary OPERA platform, with lead programs aimed at alpha-1 antitrypsin deficiency (AATD) and urea cycle disorders. The stock was trading lower by roughly 3.69% on Tuesday, changing hands near $15.15 versus a prior-session close of $15.73. The pullback came without a clearly identified single catalyst and largely reflected traders locking in gains after a sharp multi-day advance, compounded by the elevated volatility that is typical of a small-cap clinical-stage biotech.
Profit-Taking After a Sharp Rebound
The most straightforward explanation for Tuesday's slide is simple consolidation. KRRO had staged a rapid recovery in recent sessions, rallying from roughly $13.86 in late October to a close of $15.73 on November 10, a gain of more than 13% in about two weeks. After a move of that speed, short-term traders frequently take profits, and the stock's wide intraday ranges underscore how sensitive the name is to shifting order flow. A modest giveback of a few percentage points is consistent with a stock digesting prior gains rather than reacting to new, company-specific information.
Recent Catalysts Still in Focus
Although Tuesday offered no fresh headline, the fundamental backdrop that powered the prior rally remains intact. On November 5, Korro reported third-quarter 2026 results, posting a GAAP loss of $0.98 per share, narrower than the roughly $1.14 per-share loss analysts had expected. Management also disclosed cash and equivalents of about $124.8 million, which it expects to fund operations into the second half of 2028. The quarter's update was accompanied by pipeline progress: Korro has begun dosing healthy volunteers with KRRO-121 in the ANCHOR Phase 1/2 trial for urea cycle disorders, and it reported best-in-class preclinical data for KRRO-111 in AATD, including transcript editing efficiency above 95%. These milestones helped lift the stock, but they also left the shares vulnerable to a breather once the initial enthusiasm faded.
Sector and Market Sentiment
The pullback also aligns with the broader risk environment. Clinical-stage biotechnology names carry a high beta, and KRRO in particular has exhibited a beta well above 2.0, meaning it tends to move far more than the broader market on any given day. After a period in which healthcare and biotechnology stocks outperformed a tech-led selloff, risk appetite has been choppy, and speculative biotechs with limited float can trade lower on relatively light volume as sentiment cools. The absence of a defined catalyst suggests the decline was driven more by positioning and macro tone than by a change in Korro's underlying story.
Market Context and Trading Activity
Korro's shares have been unusually volatile across recent sessions, including a November 5 earnings-day swing between roughly $11.50 and $16.00 before settling near $14.73. The stock remains well above its 50-day and 200-day moving averages, which sat near $11.70 and $12.15 respectively, so Tuesday's dip did not breach major technical support. With a market capitalization around $215 million and a relatively modest free float, the ticker can experience exaggerated intraday moves on volume that would be unremarkable for a large-cap stock. Broader indices and biotech ETFs have shown mixed direction recently, so the stock's decline did not appear to be part of a uniform sector-wide rout.
What Comes Next for KRRO
Looking ahead, investors will be focused on execution rather than valuation. Korro has said it expects to begin dosing patients with urea cycle disorders in the first half of 2027 and to report interim data from the ANCHOR trial in the second half of 2027. For KRRO-111, the company anticipates a regulatory filing in the first half of 2027. Risks remain substantial: the company generates essentially no product revenue, the Novo Nordisk collaboration was terminated, and continued cash burn is expected as trials advance. The stock's high volatility also means sentiment can shift quickly between milestone events, keeping near-term price action driven as much by positioning as by fundamentals.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are showcased in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of approaches to explore. If you are interested in data-driven strategies that adapt to changing conditions, consider reviewing the Trending AI Robots page to see which systems are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for KRRO turns positive, indicating new upward trend
KRRO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 76 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where KRRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KRRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.498). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology